← Eichor
Condition: Advanced Unresectable Hepatocellular Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Unresectable Hepatocellular Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepato
Phase 2 · 4 location(s) · Riboscience, LLC. · NCT07175441Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Phase 3 · 11 location(s) · Polaris Group · NCT05317819Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy f
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07099274A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
Phase 1 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07478302Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523529PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
Phase 2 · 1 location(s) · West China Hospital · NCT06742424A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Live
Phase 1 · 20 location(s) · Bayer · NCT06764316Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
Phase 3 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT05985798Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05751343Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With
Phase 1 · 16 location(s) · Tyra Biosciences, Inc · NCT06915753A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unrese
Phase 1/Phase 2 · 21 location(s) · Huahui Health · NCT07547553Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Phase 1 · 122 location(s) · Exelixis · NCT05176483The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Unde
Phase N/A · 1 location(s) · Ruijin Hospital · NCT06746194CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
Phase 2 · 5 location(s) · TaiRx, Inc. · NCT05257590Observational Study Protocol: LIVER-R
Phase N/A · 159 location(s) · AstraZeneca · NCT06252753A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit
Phase 1/Phase 2 · 64 location(s) · Bristol-Myers Squibb · NCT07291076A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectab
Phase 1/Phase 2 · 21 location(s) · Tvardi Therapeutics, Incorporated · NCT05440708Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen
Phase 1/Phase 2 · 49 location(s) · Pfizer · NCT07227012Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06397222HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
Phase 2 · 3 location(s) · Sun Yat-sen University · NCT06737913Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT05992584ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
Phase 2 · 51 location(s) · Abbisko Therapeutics Co, Ltd · NCT07327034Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversio
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07560488A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be
Phase 2 · 3 location(s) · Asan Medical Center · NCT07010497Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Phase 2 · 12 location(s) · Replimune, Inc. · NCT05733598Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy
Phase 2 · 1 location(s) · CHA University · NCT07493668MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life
Phase N/A · 24 location(s) · AstraZeneca · NCT07607769Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)
Phase 2/Phase 3 · 1 location(s) · Tuen Mun Hospital · NCT07293468Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access an
Phase 2 · 1 location(s) · Mayo Clinic · NCT06265285
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.